Clinical and biochemical assessment of the severity of pneumosclerosis of different origin by Rodionova, V. et al.
56 Znanstvena misel journal №45/2020 
this advice may be considered as a preventive measure 
against disease development and complications. 
3. After processing the questionnaires, we have 
grounds to develop further recommendations on nutri-
tion and daily routine that accompany standard treat-
ment regimens to avoid complications of abnormal ret-
inal conditions and worsening of the quality of vision. 
4. Analysis of answers in questionnaires is rea-
sonable through determining indices to perform inte-
gral evaluation of lifestyle. Rationality index of recom-
mendations through “recommended/not recom-
mended” ratio is the most suitable. 
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Анотація 
Під спостереженням знаходились дві групи пацієнтів: 1 – пацієнти з ідіопатичним фіброзом легень та 
2 – з системним склерозом, що мали рентгенологічні ознаки пневмосклерозу. Було показано, що візуально-
аналогова шкала не є достатньо валідним інструментом для оцінки тяжкості стану пацієнта. Для оцінки 
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тяжкості стану у пацієнтів обох нозологічних форм рекомендуються шкала задишки mMRC та модифіко-
вана шкала Вуда-Даунса. Визначення активності матриксних металопротеїназ 2 і 9 та їхніх комплексів 
можна розглядати як додатковий прогностичний показник фіброзного процесу в легенях. 
Abstract 
There were observated two groups of patient: 1 – patients with idiopathic pulmonary fibrosis and 2 – with 
systemic sclerosis, which had radiological signs of pneumosclerosis. It was shown that the visual analogue scale 
is not a sufficiently valid tool for assessing the severity of the patient's condition. The mMRС dyspnea scale and 
the modified Wood-Downs scale are recommended to assess the severity of the condition in patients of both 
nosological forms. Determination of the activity of matrix metalloproteinases 2 and 9 and their complex forms can 
be assessed as additional prognostic indicator of the fibrotic process in the lungs. 
Ключові слова: пневмосклероз, ідіопатичний легеневий фіброз, системна склеродермія, матриксні 
металопротеїнази 2 і 9. 
Keywords: pneumosclerosis, idiopathic pulmonary fibrosis, systemic sclerosis, matrix metalloproteinases 2 
and 9. 
 
Pneumosclerosis is a pathological process in 
which connective tissue replaces normal lung tissue 
leading to the development of progressive respiratory 
insufficiency. Typically, pneumosclerosis develops as 
a complication of different lung diseases, but when the 
etiological cause cannot be established, the condition is 
referred to as idiopathic pulmonary fibrosis (IPF). De-
pending on the origin of the disease, P. Wolters et al. 
suggest separating pulmonary fibrosis into four groups: 
1) driven by epithelial cell dysfunction (e.g., IPF); 2) 
driven by inflammatory process (systemic sclerosis, 
rheumatoid arthritis, sarcoidosis, nonspecific intersti-
tial pneumonia, etc.); 3) developed due to occupational 
exposures or medications (silicosis); 4) smoking-re-
lated (desquamative interstitial pneumonia, respiratory 
bronchiolitis associated with interstitial lung disease, 
etc.) [1]. Despite various causes of pneumosclerosis, all 
forms of the disease lead to impaired pulmonary venti-
lation and bronchial drainage, lymph and blood circu-
lation. 
Identification of etiological causes, factors and pa-
rameters of pneumosclerosis progression is required 
not only for correct diagnosis but also for selection of a 
further strategy of treatment which in the vast majority 
of cases is aimed at eliminating the underlying pathol-
ogy and treating chronic pulmonary insufficiency. 
Prognosis may be relatively favorable when the pri-
mary condition is identified and specific treatment 
methods are used, including immunosuppressive ther-
apy [2]. As for IPF the true etiological cause of the dis-
ease is extremely difficult to establish. At the same 
time, IPF is characterized by a steady progression and 
high mortality: the average survival of patients with IPF 
is between 2 and 5 years [3, 4]. In view of the above, 
early diagnosis of the disease using a procedure which 
includes analysis of results of clinical examination, la-
boratory tests, high-resolution computed tomography, 
surgical or bronchoscopic lung biopsy is highly im-
portant [5-7].  
It should be noted that IPF diagnosis and progno-
sis remain a challenge even with all the recommended 
screening procedures done. Since a surgical procedure 
performed to obtain pulmonary biopsy specimen is as-
sociated with a high risk of complications [8], a crucial 
task is to find non-invasive markers that can be used as 
additional tools for diagnosis, assessment of the sever-
ity and prognosis of the disease. 
One of the promising areas is investigation of ma-
trix metalloproteinases (MMP), which are the calcium-
dependent enzymes involved in proteolytic degradation 
and renewal of connective tissue. The pathobiology of 
IPF is associated with an excessive synthesis of extra-
cellular matrix (ECM) components and disturbed ECM 
remodeling mediated by MMPs. Basic research and 
clinical studies showed an association between the 
level and activity of some of the 27 currently known 
MMPs and the development of IPF and its complica-
tions [9, 10]. Although the role of gelatinases, or 
MMP2 and MMP9, is most often discussed in the liter-
ature, the diagnostic significance of these enzymes in 
assessing the severity and prognosis of the disease in 
patients with pneumosclerosis of different etiologies re-
mains under question.  
The aim of the study: to establish clinical and bi-
ochemical parameters for assessment of the disease se-
verity and prognosis, based on the results of compara-
tive analysis of clinical data, VAS (Visual Analogue 
Scale) score and activity of gelatinases in patients with 
pneumosclerosis of different etiology.  
Materials and methods. Thirty-four (34) patients 
with idiopathic pulmonary fibrosis (IPF), including 24 
women and 10 men between 41 and 79 years of age 
(mean age: 57.56 ± 1.55) participated in this study. IPF 
diagnosis was based on the clinical and radiographic di-
agnostic and treatment criteria recommended by 
ATS/ERS/JRS/ALAT and the Association of Tubercu-
losis Specialists and Pulmonologists of Ukraine [5, 11].  
The second nosological group included 28 patients 
with systemic sclerosis with radiographic signs of 
pneumosclerosis. Systemic sclerosis (SS) was diag-
nosed according to the clinical and radiographic criteria 
of the American College of Rheumatology, and the 
2009 European League against Rheumatism (EULAR) 
recommendations [12]. Patients with sclerosis included 
one man and 27 women with radiographic signs of 
pneumosclerosis, between 19 and 62 years of age 
(mean age: 39.52±2.11) and the mean duration of the 
disease of 14.29 ± 1.33 years. 
Patients were enrolled in the study if the following 
inclusion criteria were met: signing of an informed con-
sent form, age between 40 and 80 years, a verified 
IPF/SS diagnosis with pneumosclerosis. Exclusion cri-
teria included history of any other lung pathology, 
bronchial asthma, HIV/AIDS, hepatitis B and/or C, tu-
berculosis of any localization, cancer, and/or surgery 
performed within 1 year before the study. 
All patients underwent examination and treatment 
in specialized pulmonology and rheumatology in-pa-
tient facilities. The examination was performed on ad-
mission and after 1 month of monitoring and treatment, 
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and included documenting complaints and medical his-
tory, anthropometric measurements, calculation of 
body mass index, and measurement of blood oxygen 
saturation using a pulse oximeter. In addition, to evalu-
ate the severity of dyspnea, mMRC (Modified Medical 
Research Council) Dyspnea Scale was used. Patients 
also underwent high-resolution computed tomography 
(HRCT) and other general clinical tests according to 
their diagnosis [13, 14]. The standard IPF and SS treat-
ment protocol was in line with international and domes-
tic guidelines [4, 14]. 
Global severity was assessed using a VAS scale, 
for which the patient was asked to choose a point on a 
10 cm scale reflecting his/her subjective feeling of what 
difficulties cause him/her clinical manifestations of the 
pulmonary pathology. The severity was evaluated 
based on the following symptoms: shortness of breath 
during exercise, shortness of breath at rest, coughing, 
sputum production, chest pain, fatigue, weight loss, 
palpitations. A patient was explained that the starting 
point (left) corresponded to a good condition, and the 
end point (right) to a bad condition. The patient had no 
information on the interpretation of the severity scale. 
After self-assessment of severity by the patient, 
the severity score was interpreted as follows: mild (0-2 
cm), moderate (2-5 cm), severe (5-10 cm). The VAS 
score of >5 cm is considered to have a negative effect 
on the patient's quality of life.  
Clinical data were analyzed using modified 
Wood-Downes Scoring System (Table 1) [15]. 
Table 1 
Modified Wood-Downes Scoring System 
Severity 1  2 3 
Respiratory rate 
Normal or exceeding the 
age-appropriate reference 
value by up to 30% 
Exceeds the age- appropri-
ate reference value by 30-
50% 
Exceeds the age- appropri-
ate reference value by 
>50%  
Oxygen saturation >95% 90-95 % <90 
Auscultatory 
findings 
Moderate wheezing at the 
end of exhalation 
"Mosaic" breathing pat-
tern, significant wheezing 
during exhalation 
Weakened breathing, sig-
nificant wheezing during 
prolonged exhalation, 
crackles 
Use of accessory 
muscles for respira-
tion 
No 
Intercostal and subcostal 
muscles take part in respi-
ration (mild or moderate 
degree) 
Involvement of intercostal, 
subcostal, suprachoroidal 
muscles (significant de-
gree), paradoxical breath-
ing 
State of 
consciousness 
Not impaired Moderately exalted Exalted consciousness 
PEFR (% of the ref-
erence value) 
70-90% 50-70% <50% 
 
Based on the results of severity assessment, pa-
tients of each nosological group were sub-divided into 
two subgroups: Subgroup I included patients with 
symptoms corresponding to level 1 and 2 of severity 
according to the Wood-Downes Score; Subgroup II in-
cluded patients with symptoms of level 3 of severity. 
The control group consisted of 15 healthy volunteers of 
matching age. 
Additionally, the activities of MMP2/9 and their 
complexes were evaluated using gelatin zymography. 
This method includes the following steps: 1) electro-
phoresis of blood plasma proteins in gel containing gel-
atin, 2) incubation of gels in buffer containing calcium 
ions, 3) staining in medium containing Coomassie Bril-
liant Blue R-250, and evaluation of zones of lysis. This 
method is used for assessment of the activity of not only 
mature gelatinases, but also their pro-forms, as well as 
multienzyme complexes [16]. 
As a statistical test for group comparison, one-way 
analysis of variance (ANOVA) was used, followed by 
the Tukey test. All data are expressed as mean ± stand-
ard error of mean (SEM). Results were considered sta-
tistically significant at p<0.05. 
Results and Discussion 
Self-assessment of patients with confirmed IPF 
using VAS scale showed that 21 (61.8%) patients rated 
their condition as moderately severity and 13 patients 
(38.2%) as severe. In the group of patients diagnosed 
with SS, the distribution was as follows: 4 patients rated 
their condition as mild (14.2%), 20 (71.4%) as moder-
ate and 4 (14.2%) as severe. Comparison of the results 
of self-assessment with clinical and laboratory data 
showed an inadequate attitude of patients to their con-
dition, especially in the SS group, which may be related 
to the long course of illness, gradual development of 
symptoms and adaptation of patients to their condi-
tions. 
Results on the severity of dyspnea assessed using 
the mMRC Dyspnea Scale are summarized in Table 2, 
demonstrating more severe condition in patients with 
IPF.  
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Table 2 
Dyspnea severity in studied patient groups according to mMRC Dyspnea Scale 
 
Dyspnea grades  Total 
patients, 
n (%) 
0 1 2 3 4 
Patients with 
IPF 
0 
0 
(0%) 
5 
(14.7%) 
17 
(50%) 
6 
(17.7%) 
34 (100%) 
Patients with 
SS 
0 
3 
(10.7%) 
11 
(39.28%) 
8 
(28.57%) 
4 
(14.28%) 
28 (100%) 
 
Based on the results of evaluation of IPF patients 
using the modified Wood-Downes Scoring System, the 
patients were divided into 2 subgroups. Subgroup 1 in-
cluded 19 patients with mild and moderate disease, 
with respiratory rate (RR) of 16-19 ± 1 breaths per mi-
nute, oxygen saturation (SpO2) of 85-90%, accessory 
muscles not involved in respiration, and peak expira-
tory flow rate (PEFR) of 72-75% of normal value. In 
subgroup 2 (15 patients) the condition was assessed as 
severe, with RR of 20-27 ± 1 breaths per minute, oxy-
gen saturation of 45-70%, accessory muscles actively 
involved in respiration, and PEFR of 72-75% of normal 
value.  
Patients with с SS were also divided into 2 sub-
groups according to their disease severity based on the 
modified Wood-Downes score: subgroup 1 included 21 
patients with mild and moderate disease, with RR of 
16-18 ± 1 breaths per minute, oxygen saturation of 90-
94%, accessory muscles not involved in respiration, 
and PEFR of 72-75% of normal value. Subgroup 2 (7 
patients) included patients with severe condition, with 
RR of 20-24 ± 1 breaths per minute, oxygen saturation 
of 85-87%, accessory muscles actively involved in res-
piration, and PEFR of 72-75% of normal value.  
Gelatin zymography results showed that patients 
in study groups developed significant changes in 
plasma gelatinolytic activity over time (Table 3).  
Table 3 
Blood plasma gelatinolytic activity (AU) in studied patient groups 
Parameter  Control 
Idiopathic pulmonary fibrosis Systemic sclerosis 
mild and 
moderate  
severe mild and moderate  severe 
proMMP9  
(92 kDa) 
Day 1 
1.05 ± 0.08 1.34 ± 0.21 2.27 ± 0.25** 
2.67 ± 
0.16****/††† 
2.87 ± 0.52**/† 
After 1 
month  
2.43 ± 
0.46** 
2.72 ± 0.11***/§§ 2.24 ± 0.24 2.91 ± 0.54**/† 
MMP9 
(83 kDa) 
Day 1 
1.00 ± 0.09 1.05 ± 0.07 1.56 ± 0.07**/†† 1.26 ± 0.07 
1.84 ± 
0.25**/†† 
After 1 
month  1.37 ± 0.15 1.66 ± 0.11**/§§ 1.68 ± 0.35 1.76 ± 0.25*/§ 
MMP2 
(72 kDa) 
Day 1 
1.08 ± 0.025 1.12 ± 0.04 1.08 ± 0.01 
0.78 ± 
0.03****/†††† 
0.87 ± 0.04 
After 1 
month  1.16 ± 0.07 0.93 ± 0.14 
0.63 ± 
0.30***/§§§§/†††† 
0.78 ± 
0.13*/§§/†† 
Complex 125-
130 kDa 
Day 1 
0.84 ± 0.08 1.06 ± 0.17 1.55 ± 0.22 - - 
After 1 
month  
2.50 ± 
1.50*/† 
2.14 ± 0.20** - - 
Complex 120 
kDa 
 
Day 1 
0.91 ± 0.10 0.62 ± 0.12 0.47 ± 0.10 1.52 ± 0.20* 1.71 ± 0.88 
After 1 
month  
1.96 ± 
0.37*/§§§ 
0.81 ± 0.10 3.31 ± 1.40**/§/†† 
3.41 ± 
1.66****/§/††† 
Note: * p˂0.05, ** p˂0.01, *** р˂0.001, **** р˂0.0001 compared to control group, § p˂0.05, §§ p˂0.01, §§§ p˂0.001, 
§§§§ р˂0.0001 – compared to parameters of the respective group of patients on Day 1, †† p˂0.01, †††† p˂0.0001 – 
significance level in patients with mild and moderate idiopathic pulmonary fibrosis on Day 1. AU – arbitrary units. 
 
The data summarized in Table 3 show that the ac-
tivities of a pro-form and mature MMP9 in all study 
groups were above normal value and were associated 
with the disease severity. It should be noted that 
proMMP9 activity was significantly different in pa-
tients with IPF and SS: in the latter group it was signif-
icantly higher. In contrast, MMP2 activity did not 
change in IPF group, while in patients with systemic 
sclerosis this parameter decreased significantly, and 
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over time a further decrease in MMP2 activity was ob-
served.  
The advantage of the method chosen for assess-
ment of the activity of matrix metalloproteinases is that 
using this method different forms of MMP with gelati-
nolytic activity can be studied. For example, at the be-
ginning of testing, in IPF patients, in addition to typical 
MMP2 and MMP9, blood samples showed zones of ly-
sis of gelatin in the range of 125-130 kDa, as well as a 
zone with a molecular weight of 120 kDa. Enzymes 
corresponding to these zones were referred to as the 
125-130 kDa complex and the 120 kDa complex, re-
spectively. Our results showed that the activity of these 
complexes in patients with IPF increased significantly 
after one month of monitoring. In contrast, in patients 
with SS the 125-130 kDa complex was absent, while 
the activity in the zone of 120 kDa significantly ex-
ceeded normal value and was 2-3 times higher than that 
in the IPF group, and in addition was associated with 
the severity of the disease. 
Analysis of publications suggests that the 125-130 
kDa form is an MMP9 complex with lipocalin. 
Lipocalin is expressed in very low concentrations in 
many human tissues, but is mostly synthesized by neu-
trophils, therefore, in the literature it is most frequently 
referred to as neutrophil gelatinase-associated lipocalin 
(NGAL) [17]. Human neutrophils simultaneously ex-
press NGAL and gelatinase B (MMP9, 92 kDa), which 
are stored in specific granules and secreted upon acti-
vation of these cells. In this case, NGAL can be se-
creted both as a monomer and as a heterodimer, in form 
of a complex with MMP9 with a molecular weight of 
125 kDa. Apparently, the increase in the activity of the 
125-130 kDa complex that we observed in the blood of 
patients with IPF, was associated with the involvement 
of neutrophils in the development of pneumosclerosis. 
There are studies supporting this hypothesis that 
demonstrated that NGAL expression was associated 
with inflammation and proliferation processes, endo-
thelial dysfunction, and other pathological conditions 
[18-20]. Further, evidence suggests that formation of 
MMP9/NGAL complexes help to preserve the activity 
of this gelatinase and improve lung oxygenation [21]. 
As to the 120 kDa complex, no evidence was found. 
Apparently, analysis of composition of this complex 
could provide additional information about the mecha-
nisms causing its increase in patients with systemic 
sclerosis and its possible role in the pathogenesis of this 
disease. 
Conclusions 
1. To assess the severity of dyspnea in patients 
with IPF and SS complicated by pneumosclerosis, we 
recommend using mMRC scale. 
2. Visual analogue scale cannot be considered a 
valid tool for disease severity assessment. For clinical 
data analysis, the modified Wood-Downes Scoring 
System is suggested for severity assessment in patients 
with IPF and SS complicated by pneumosclerosis. 
3. Evaluation of the activity of MMP2/9 and their 
complexes can be used as an additional prognostic pa-
rameter of pulmonary fibrosis and reflect the severity 
of the pathological process.  
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Abstract 
Early diagnosis of the initial degree of generalized parodontitis (GP) is an effective way of secondary pre-
vention. The aim of this research was to develop a protocol for the treatment of GP in patients with AN. The object 
- 60 patients (mean age 26±3.8 years), with a diagnosis of GP, I-II degree, chronic, and AN, restrictive, which by 
simple randomization were divided into three groups (randomized by sex, age of patients, underlying and comor-
bidy diagnosis) to study the clinical effectiveness of our proposed method. Clinical, radiological, hygienic, immu-
nological, biochemical, psychological and statistical methods were used. Thus, as a result of the proposed treat-
ment protocol, the largest number of satisfactory treatment results was observed in group III patients (85.0±8.0%) 
with the inclusion of drugs that affect the pathogenetic mechanisms of the disease, including normalization of local 
immunity, markers of decline oxidative-antioxidant stress, radiological data of normalization of bone tissue of the 
alveolar process, a tendency to reduce microbial and tissue sensitization. 
Keywords: generalized parodontal diseases, generalized parodontitis, hypersensibilisation, anorexia nervosa, 
microbial allergy, osteoporosis. 
 
Generalized parodontal diseases (GPD) 
consistently occupy one of the leading places in the 
structure of dental diseases. According to 
epidemiological researches, these diseases affect more 
than 95% of the world's population over 45 years, and 
among people aged 31-44 years, the prevalence of 
pathology is over 75%, which indicates not only high 
levels of morbidity, but also a significant reduction in 
the patients’age [1]. In the structure of parodontal 
diseases, 90% of it are inflammatory and dystrophic-
inflammatory processes and the authors note a steady 
trend towards the predominance of dystrophic-
